DLA PIPER LLP (US)

Lobbying for BIOHAVEN PHARMACEUTICALS, INC. · A biopharmaceutical company.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · Connecticut · House · Senate · $60,000.00 income · posted Jul 21, 2025

Lobbying activity 1

Health Issues

Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.